NewAmsterdam Pharma Dives Despite Cholesterol Treatment …

Nov 20, 2024 · Related news NewAmsterdam Pharma Stock Hits 90-Plus RS Rating. 12/11/2024 NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD …

CouponFollow Extension

2%
OFF

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A …

3 weeks from now

The company's combination of drugs called obicetrapib and ezetimibe reduced LDL cholesterol by an average 52.2% after 84 days. At the median, the reduction was 54%. The combination …

msn.com

50%
OFF

NewAmsterdam Pharma Shares Fall After Cholesterol Treatment …

3 weeks from now

Nov 20, 2024 · NewAmsterdam Pharma crashed Wednesday after the company said its experimental cholesterol treatment lowered "bad" LDL by roughly 50%The post …

newsminimalist.com

42%
OFF

Biotech Stock: NewAmsterdam Cholesterol Drug Study Results Fall …

3 weeks from now

Jul 29, 2024 · NewAmsterdam Pharma said Monday its experimental drug lowered "bad" LDL cholesterol by almost 42% over a year, but the results were slightly below expectations. The …

investors.com

50%
OFF

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A …

3 weeks from now

Nov 20, 2024 · NewAmsterdam Pharma crashed Wednesday after the company said its experimental cholesterol treatment lowered "bad" LDL by roughly 50% The post …

ishookdaily.com

41%
OFF

NewAmsterdam Leaps On Positive Trial Results | The Pharmaletter

3 weeks from now

Dec 11, 2024 · Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. …

thepharmaletter.com

$479
OFF

NewAmsterdam Pharma: Science-Backed And Patient-Focused

3 weeks from now

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to …

newamsterdampharma.com

1%
OFF

Why Is NewAmsterdam Pharma Stock Trading Higher On …

3 weeks from now

Dec 10, 2024 · The treatment discontinuation rate for the obicetrapib arm was 11.1% versus 12.4% for the placebo. Price Action: NAMS stock is up 33.6% at $24.74 at last check Tuesday. …

benzinga.com

32%
OFF

NewAmsterdam Pharma's Focus: Cardiovascular Disease

3 weeks from now

As a whole, cardiovascular disease (CVD) is the leading cause of death globally, representing 32% of all deaths. 1,2 CVD can be caused by a variety of lifestyle, environmental, and medical …

newamsterdampharma.com

FAQs about NewAmsterdam Pharma Dives Despite Cholesterol Treatment … Coupon?

Does newamsterdam Pharma's cholesterol drug lower cardiovascular risk?

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted. ...

Should one avoid limes if they are on statins?

There are no scientific reports that prove the interaction between statins and limes. Therefore, there is no reason to avoid its consumption. ...

Will newamsterdam pharma stock open below a cup base?

But they fell short of the a midstage study called Rose2 where the two drugs led to an average 59% reduction in LDL cholesterol. In premarket trades, NewAmsterdam Pharma stock tumbled more than 7% to 21.97. Shares look likely to open below the lower boundary of a cup base they're currently forming, MarketSurge shows. ...

Does Amsterdam Pharma's cholesterol drug lower risk of heart attacks?

N ewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events — like a heart attack or stroke — and the biotech stock catapulted. Please watch the video at Investors.com - How To Buy Stocks: Cup With Handle Chart Pattern ...

What happened to newamsterdam stock?

NewAmsterdam stock skyrocketed 41.4% to close at 26.19. Shares opened at their highest point since November 2022. The biotech stock broke out of a buy point at 25.32 out of a cup-with-handle base, according to MarketSurge. NewAmsterdam tested obicetrapib in patients who don't have controlled LDL cholesterol. ...

Does newamsterdam's obicetrapib lower cardiovascular risk?

NewAmsterdam Pharma (NAMS) said Tuesday its cholesterol drug lowered the risk of major cardiovascular events — like a heart attack or stroke — and the biotech stock catapulted. Over the course of a year, patients who received NewAmsterdam's obicetrapib had a 21% lower risk of having a major cardiovascular event, the company said in a news release. ...